



The relative strengths and weaknesses of Viracta Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viracta Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 40% points. The greatest weakness of Viracta Therapeutics Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is 209%, being 54% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	46,988
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,999
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-4.0
Other Expenses	939
Other Liabilities	0
Other Net Income	3,565
Other Revenues	3,061
Property and Equipment	14
Research and Development	23,701
Selling, General and Administrative Expense	18,662

Output Variable	Value in 1000 USD
Assets	47,002
Liabilities	18,999
Expenses	43,302
Revenues	3,061
Stockholders Equity	28,003
Net Income	-36,676
Comprehensive Net Income	-36,678
BaseVar	57,966
ECR before Limited Liability	74%
Economic Capital Ratio	209%